- Metabolic Stability
- CYP Interaction
- Permeability & Transporters
- Physicochemical Properties
- Protein Binding
Discovery PK and Toxicology
Dr. John Kapeghian, Ph.D., DABT, joins Frontage with over 35 years of experience in global preclinical safety evaluation and development. After working in regulatory and experimental toxicology units at large pharma (Ciba now Novartis) and in contract research (Sierra Biomedical/Charles River), he established his own company, Preclinical Safety Associates, which provides toxicology strategy and regulatory services for over 90 companies worldwide since 2006.
Frontage welcomes James Huang, Ph.D. as Vice President, Corporate Quality Assurance. James is a highly experienced quality and compliance professional with over thirty years of experience. He has a proven track record of success in transforming and modernizing quality operations, ensuring global regulatory compliance, and governance strategies.
Stewart is an accomplished executive, with over twenty years of experience in scientific program management, toxicology and toxicologic pathology, strategic planning, and business development in preclinical contract research. Prior to joining Frontage, Stewart was a site and divisional leader at Inotiv with responsibilities spanning multiple laboratory sites focused on pathology, DMPK (drug metabolism/pharmacokinetics), molecular and cell biology, flow cytometry, and small and large animal vivarium operations.
Frontage Holdings Corporation today announced that Dr. Abdul Mutlib has been promoted to CEO of the company, a role in which he succeeds Frontage’s founder Dr. Song Li, who will remain as Executive Chairman of the Board of Directors. Dr. John Lin has been promoted to President of Frontage Laboratories, Inc., the company’s wholly-owned subsidiary. Dr. Mutlib and Dr. Lin will each assume their new roles effective as of today. As Executive Chairman, Dr. Li will continue to actively participate in the company’s leadership and focus on strategic growth opportunities.